Similar Posts
Come Work With Us!
Our Medical Decision Making Research Group is looking for an Associate in Research to join our team. Please see the job description below and the link to apply. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The Associate in Research (RA) will support investigators on multiple research projects related to patient decision making and health communication. The RA will contribute to the…
Houston (and the Rest of the US Healthcare System): We Have a Price Problem
Want to know why we spent so much on healthcare in United States? There are lots of reasons. Our population is aging, the rate of diabetes is rising, and the healthcare industry keeps developing wonderful but expensive new technologies to treat our ailments. But more than anything, we have a price problem. It’s price increases…
Peer Comparison Can Reduce Antibiotic Prescribing
Very interesting article in the Lancet recently, from the nudge unit in the United Kingdom. They give physicians feedback on how much they prescribed antibiotics compared to their peers, and found that such feedback reduced antibiotic prescriptions. I hope to see more of this work!
Charging Copays and Deductibles During a Pandemic Is Foolish—and Deadly (Newsweek)
In areas of the country hardest hit by COVID-19, clinicians are already being forced to make tragic rationing decisions: about who to admit to the hospital, who to transfer to the ICU and who to place on scarce ventilators. These decisions feel out of character with our national identity. We normally think of ourselves as…
Think Fast and You'll Lose Money Quickly (A Behavioral Economics Explanation of Irrational Gambling)
Shutterstock I have just given you $78. (I’m a generous guy.) Now I’m giving you a choice: you can enter a lottery where you have a 75% chance of losing that $78 and a 25% of keeping it, or you can hold on to $20 and avoid the lottery all together. Quick—tell me what you…
Cancer Drugs Aren't As Cost-Effective As They Used To Be
Cancer drugs have become increasingly expensive in recent years. No one blinks anymore when a new lung cancer or colon cancer treatment comes to market priced at more than $100,000 per patient. In part, we don’t blink because we have simply gotten used to such prices – the shock has worn off. Moreover, many of…